U.S. FTC clears Valeant deal for Medicis Pharmaceutical
(Reuters) - The U.S. Federal Trade Commission has cleared Valeant Pharmaceuticals International Inc's (VRX.TO) $2.6 billion deal to buy U.S. dermatology rival Medicis Pharmaceutical Corp MRX.N, without conditions, Valeant said on Friday.
The combined company is set to dominate the U.S. dermatology market. Medicis led that market in gross sales in 2011, while Valeant, Canada's biggest public drugmaker, ranked third, Valeant said when the deal was first announced.
Last December, when the FTC approved Valeant's acquisitions of the dermatology units of Sanofi (SASY.PA) and Johnson & Johnson (JNJ.N), it forced the firm to sell off the rights to three drugs.
Valeant, on the acquisition trail since its 2010 takeover by Biovail Corp, which assumed the Valeant name, has favored segments where patients often pay out of pocket, such as ophthalmology and dermatology, cutting its exposure to cost-sensitive insurers.
Medicis' products include Solodyn, a prescription acne tablet, Restylane, an injectable filler, and Dysport, a competitor to Allergan Inc's (AGN.N) Botox anti-wrinkle treatment. (Reporting by Allison Martell; editing by John Wallace)
WASHINGTON - The Federal Reserve on Wednesday embarked on the risky task of winding down the era of easy money, saying the U.S. economy was finally strong enough for it to start scaling down its massive bond-buying stimulus. | Video
WASHINGTON - Start-up companies will be able to raise much more capital through certain public stock deals without facing costly regulatory burdens under a proposal announced by U.S. securities regulators on Wednesday.
BEIJING/HONG KONG - China reiterated its opposition on Thursday to a European Union plan to limit airline carbon dioxide emissions and called for talks to resolve the issue a day after its major airlines refused to pay any carbon costs under the new law.